Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib-Reference-Cited by-同舟云学术

Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib

Published:2011-10-11 Issue:4 Volume:26 Page:824-826
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Georgiou G,Efthymiou A,Vardounioti I,Boutsikas G,Angelopoulou M K,Vassilakopoulos T P,Kyrtsonis M-C,Plata E,Tofas P,Bitsani A,Bartzi V,Pessach I,Dimou M,Panayiotidis P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2011280.pdf

Reference11 articles.

1. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041–6605.

2. Groves MJ, Sales M, Baker L, Griffiths M, Pratt N, Tauro S . Factors influencing a second myeloid malignancy in patients with Philadelphia-negative-7 or del(7q) clones during tyrosine kinase inhibitor therapy for chronic myeloid leukemia. Cancer Genet 2011; 204: 39–44.

3. Pawarode A, Sait SN, Nganga A, Coignet LJ, Barcos M, Baer MR . Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities. Leuk Res 2007; 31: 1589–1592.

4. Schafhausen P, Dierlamm J, Bokemever C, Btuemmendorf TH, Bacher U, Zander AR et al. Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with imatinib. Cancer Genet Cytogenet 2009; 189: 63–67.

5. Dvorak P, Hruba M, Subrt I . Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia. Leuk Res 2009; 33: 860–861.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP‐CML) exist? That is the question.;British Journal of Haematology;2021-08-15

2. Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy;International Journal of Hematology;2021-01-05

3. Case Report of acute myeloid leukemia with “WT1, ATRX, CEBPA, CSMD1, IKZF1, and LRP1B mutation and translocation between chromosome 1 and 19” developing from Philadelphia-negative chronic myeloid leukemia after TKI therapy;Medicine;2020-01

4. Gelatinous bone marrow transformation and emergence of clonal Philadelphia-negative cytogenetic abnormalities with excess blasts in a patient with chronic myeloid leukemia treated with dasatinib;Anti-Cancer Drugs;2019-04

5. Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review;Annals of Hematology;2018-02-06